Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Volatility
“Iovance Biotherapeutics faces heightened share price swings amid its shift to commercial operations with Amtagvi for advanced melanoma, posting a 7.2% daily gain against an 8.66% monthly drop. Valuation appears undervalued at $2.53 per share, with analyst targets averaging $8.35-$10.50, driven by projected $250-300 million in 2025 revenue, though ongoing losses and execution risks persist.” … Read more